North American Scientific (NAS) subsidiary Theseus Imaging has inked a clinical trial agreement with the National Cancer Institute for the co-development of the Chatsworth, CA-based firm's Hynic-Annexin V agent for imaging cell death. The agreement provides for cooperation between Theseus and the NCI's Biomedical Imaging Program (BIP).
In addition, both parties will plan for clinical development of the agent, and will also submit their own investigational new drug (IND) applications to the Food and Drug Administration. The BIP will also sponsor clinical trials in oncology patients, NAS said.
By AuntMinnie.com staff writersFebruary 18, 2003
Related Reading
Theseus withdraws IND application, January 21, 2003
NAS begins direct sales of brachytherapy seeds, posts year-end results, December 17, 2002
NAS adds to executive roster, October 3, 2002
Theseus seeks FDA IND for new agent, September 17, 2002
NAS ups sales, trims losses in Q3, August 20, 2002
Copyright © 2003 AuntMinnie.com
